SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Thursday, August 22, 2013

The BDR compulsory licensing application and the BMS ‘Statements of Working’

Posted on 12:08 AM by Unknown
It has been almost 6 months since BDR Pharmaceuticals filed a compulsory licensing application for the Dastinib patent owned by BMS. We had written about it over here. There has been little news about this CL and so we did a bit of prodding around. And as always the online records of the patent office are incomplete – so we do the next best thing – speculate! 

As per the documents we found on the Patent Office’s website, it appears that BDR Pharmaceutical’s application for a CL was in serious jeopardy, a few months ago. As per this petition for condonation of delay filed by BDR, four months, after the initial application for the CL was filed in March. Apparently, in May, the CG had issued a notice to BDR informing it that it had not made out a prima facie case for grant of a CL – if a prima facie case is not made the CG can reject the CL application. I’m not quite clear on what happened next but BDR appears to have tried re-negotiating a voluntary licence with BMS, after which it submitted more information and a request for the Controller to find a prima facie case for grant of compulsory licence. This last request appears to have been made after some deadline because of which it was accompanied by an application for condonation of delay. We don’t know what happened after this petition. 

While we are on the topic of Dastinib, we might itself point out the manner in which BMS has been filing its Form 27 or statement of workings. Here’s an affidavit from BMS explaining the delay in filing a Form 27 for the year 2008, four years later in 2012. If that delay was not enough, BMS filed the Form 27 for 2012 on July 31, 2013 i.e. four months after the March 31, 2013 deadline. 

May I add that we had mailed the Patent Office on 30th July, 2013 asking for a copy of the Form 27 and voila – the very next day BMS files a Form 27 with a bland Rule 137 petition without any reasons for the delay in filing the same. Why is the Patent Office allowing these Rule 137 petitions without passing any reasoned orders?
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Compulsory Licensing, Indian Pharma, Patent | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Ghost Post: Samsung v. Apple Presidential Enforcement Veto
    SpicyIP subscribers recently received a short blurb from Shamnad on this FT article regarding the hypocrisy of stamping 'national inter...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
    Image from here Recently, as The Hindu reports , Pedana Kalamkari art form received GI protection. Members of Vegetable Dye Hand Block Kalam...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ▼  August (41)
      • SpicyIP Tidbit: ALCS August Distribution
      • PIP Essay Competition Results Announced: Meet the ...
      • Now Showing: Satyagraha: Bom HC denies an Injuncti...
      • Patenting food: Plumpy’ Nut and more?
      • Bollywood flick Satyagraha faces dispute over its ...
      • Leading IP Academics Fired: Protest Petition Again...
      • Two MHRD IP Chair Professors axed; Reasons unknown
      • FICCI and The George Washington University, Washin...
      • SpicyIP Tidbit: IPA continues communication with P...
      • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
      • Colgate v Pepsodent: Comparative Advertising
      • SpicyIP Tidbit: Justice KN Basha to be new IPAB ch...
      • IPRS complies with new copyright law & decides to ...
      • Re-imposing curbs on royalty payments to foreigners
      • Debating the CIS Draft Bill on Privacy: Should thi...
      • The BDR compulsory licensing application and the B...
      • Satyajit Ray's sketches and copyright controversies
      • Rihanna's victory in the Topshop T-shirt case
      • When cancer drugs stop being “necessities”: A case...
      • SpicyIP Tidbit: Singers from the South in support ...
      • Loss of an IP Leader: RIP Prof Daruwalla
      • Part II: IPAB revokes Allergan's patent on eye dru...
      • Part I: IPAB revokes Allergan's patent on eye drug...
      • Feedback on draft guidelines for Computer Related ...
      • A naïve report from Parliament on FDI in the Pharm...
      • INTAvening in the Supreme Court: Parallel Imports ...
      • Surprising news! - Roche decides to not ‘pursue’ H...
      • Independent Intellectual Property: Gunning For (or...
      • SpicyIP Tidbit: Special Services announced by WIP...
      • GI News: Kaipad Rice, Nagpur Oranges, Dharmavaram ...
      • SpicyIP Tidbit: Patent Office confirms status of G...
      • The Sholay litigation saga
      • SpicyIP Tidbit: Has Genentech’s main Herceptin pat...
      • Bollywood flick 'I love NY' accused of plagiarisin...
      • The Herceptin patent fiasco at the Indian Patent O...
      • IPO vs IPAB: IT Prowess and Transparency?
      • Ghost Post: Samsung v. Apple Presidential Enforcem...
      • Delhi HC dismisses Rediff.com's Copyright Infringe...
      • UNICEF Supply Annual Report 2012 : India is the La...
      • Raj Anand Moot Court Competition 2013
      • Breaking News: GSK patents challenged: IPAB revoke...
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.